Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBP-245 for Verruca Vulgaris
NCT04253912Phase 2Unknown
- Sponsor
- Veloce BioPharma
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VBP-245 in verruca vulgaris (2 arms), sponsored by Veloce BioPharma. Primary endpoint: Decrease in wart diameter at 12 weeks. Status: unknown.
02
Drugs
VBP-245
03
Conditions
verruca vulgaris
Beyond the preview
Go deeper on NCT04253912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253912.